Anti-Human Fc gamma RIIB/CD32b Reference Antibody (BI-1206, RUO)

Catalog No.	HB103036
Brand	abinScience
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS pH 7.4
Purity	>95% purity as determined by SDS-PAGE.
Isotype	IgG
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target	IGFR2, FCG2, Fc-gamma RII-b, CDw32, FcRII-b, IgG Fc receptor II-b, CD32, Fc-gamma-RIIb, Low affinity immunoglobulin gamma Fc region receptor II-b, FCGR2B
References	1. Jiang VC, et al., Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. J Hematol Oncol. 2022 Apr 11;15(1):42. [HB103036] 2. Changying Jiang, et al., BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma, Blood, Volume 134, Supplement 1, 2019, Page 2863, ISSN 0006-4971. [HB103036] 3. Mårtensson, L.et al., A novel FcγRIIB-blocking antibody to enhance FcγR-dependent antitumor immunity with anti-HER2 therapy[J]. Cancer Research, 2022, 82(12_Supplement): 3423-3423. [HB103036]
Purification	Protein A/G purified from cell culture supernatant.
Biological activity	BI-1206 (5 ug/mL, 0-5 h) blocks Rituximab (5 ug/mL)-induced and Rituximab-based combination with Ibrutinib or Venetoclax or CHOP-induced CD20 internalization effectively in JeKo-1 cells [1]. BI-1206 (10 mg/kg, i.v., twice a week) is highly potent in blocking tumor growth in Ibrutinib-Venetoclax dual resistant MCL PDX (PDX-A) NSG mice model [1]. BI-1206 (10 mg/kg, i.v., twice a week) inhibits tumor growth when combined with Rituximab in Rituximab-Ibrutinib-CAR T-triple resistant MCL PDX (PDX-B) NSG mice model [1]. BI-1206 (10 mg/kg, i.v., twice a week for 14 d) has better efficacy and prolonged survival in the triple combination group with Ibrutinib or Venetoclax compared to dual combinations without BI-1206 in JeKo-1 CDX mice model [1]. BI-1206 (10 mg/kg, i.v., twice a week) shows superior anti-tumor activity and prolonged survival when combined with Venetoclax compared to any single or dual combination in Ibrutinib-Rituximab-Venetoclax triple-resistant MCL PDX (PDX-C) model [1].
Endotoxin level	< 10 EU/mg
Expression system	Mammalian cells
Accession	P31994
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative name	BI-1206, BI1206, BI1206
Clone ID	BI-1206
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1, lambda Isotype Control antibody (HyHEL-10) (HP248107)